x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230508
| Product Information | |
|---|---|
| CAS No. | 1402836-58-1 |
| Synonyms | 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol, IDO inhibitor |
| Formula | C18H22N2O |
| Molecular Weight | 282.4 |
| Target | IDO1 |
| Product Description | NLG919 is an orally available potent inhibitor of the indoleamine-2,3- dioxygenase (IDO1) pathway, a crucial pathway involved in allergic inflammation that mediates immunosuppressive effects through metabolization of tryptophan to kynurenine. NLG919 affects differentiation and proliferation of T cells by inducing downstream signaling via GCN2, mTOR and AHR, with values of Ki = 7 nM and EC50 = 75 nM. NLG919 is being investigated for the treatment of immunosuppression associated with cancer. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Store as supplied at or below -20 °C for up to 3 years. Stable in DMSO at -80 °C for up to 6 months. |
| Solubility Overview | Soluble in DMSO at 15 mg/mL. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
